Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | OGG1 | O15527 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032888 | 0.82 | — | — | |
| SCHEMBL1476030 | 0.81 | GRM5 (0.55) | GRM5ALDH1A1MAPK8MAPK10KDM4E | |
| SCHEMBL20428951 | 0.78 | GRM5 (0.49) | GRM5ALDH1A1LMNAKDM4ECYP2D6 | |
| SCHEMBL107709 | 0.77 | S100A4 (0.48) | GRM5ALDH1A1KDM4EP2RX7GAA | |
| SCHEMBL18568508 | 0.77 | GRM5 (0.55) | GRM5MAPK8MAPK10HDAC1HDAC8 | |
| SCHEMBL28901800 | 0.76 | GRM5 (0.43) | GRM5ALDH1A1LMNAMAPK8MAPK10 | |
| SCHEMBL28878477 | 0.76 | HTR2B (0.42) | ALDH1A1LMNAP2RX7CYP2C19GAA | |
| Bromide SCHEMBL27274495 | 0.76 | GRM5 (0.41) | GRM5ALDH1A1LMNAMAPK8MAPK10 | |
| SCHEMBL19718381 | 0.76 | KDM4E (0.39) | ALDH1A1LMNAKDM4EP2RX7MPO | |
| SCHEMBL1706430 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109265443-B | Heterocyclic compounds as ASK inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2022-11-29 | — | — | CN | disclosed |
| EP-3572401-B1 | ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| CN-107108598-B | Thiazoles as Ror gamma t modulators | 詹森药业有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-RE48150-E1 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10307427-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3083615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3083615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2019-04-17 | — | — | EP | disclosed |
| CN-109265443-A | Heterocyclic compound and its application as ASK inhibitor | 南京圣和药业股份有限公司 | 2019-01-25 | — | — | CN | disclosed |
| WO-2019015559-A1 | HETEROCYCLIC COMPOUND ACTING AS ASK INHIBITOR AND USE THEREOF | 南京圣和药业股份有限公司 | 2019-01-24 | — | — | WO | disclosed |
| EP-3212641-B1 | THIAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-05 | — | — | EP | disclosed |
| US-20130203819-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8440665-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440665-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440665-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2588475-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| CN-102985418-A | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES INC | 2013-03-20 | — | — | CN | disclosed |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2012003387-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203819-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, RIPK3 | GRM5 3196/4885ALDH1A1 3284/4885LMNA 1842/4885 |
| US-10307427-B2 | Apoptosis signal-regulating kinase inhibitors | AIFM1, DAPK1, MAP3K1 | GRM5 4176/4885ALDH1A1 2357/4885LMNA 2703/4885 |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, RIPK3 | GRM5 3196/4885ALDH1A1 3284/4885LMNA 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.